Latest Regulatory Update News

Salt Listed Funds released its 2026 annual report highlighting governance changes, investment policy updates including Treasury Units and Carbon-Related Businesses, and a notable decline in the Carbon Fund’s unit price over the year.

Diamond Infraco has extended its takeover offer for Atlas Arteria to 25 June 2026, waiving several key conditions and adjusting the timeline for regulatory updates.

OncoSil Medical has cleared a major regulatory hurdle as its Humanitarian Device Exemption application nears FDA approval, while its TRIPP-FFX trial shows promising results combining OncoSil with standard chemotherapy for pancreatic cancer.

AuKing Mining expands its footprint at the Tundulu Rare Earths Project in Malawi through a structured earn-in agreement and a fresh airborne survey revealing a larger carbonatite system with multiple new drill targets.

The Therapeutic Goods Administration has broadened the range of clinicians eligible to participate in psychedelic-assisted psychotherapy, a move set to speed up recruitment and improve patient access across Emyria’s national Empax network.

Premier1 Lithium completed its maiden RC drilling at Yalgoo and confirmed expanded gold anomalies at Rochefort through advanced geophysical surveys, setting up follow-up drilling in 2026.

The Koala Company Limited has issued corrected Appendix 3X notices for directors Daniel Milham and Michael Gordon, clarifying escrow status and relevant interests in securities. This update follows a prior announcement on substantial holder notices and aims to ensure regulatory compliance.

Radiopharm Theranostics has received a positive recommendation to escalate the dose of its 177Lu-RAD202 radiotherapeutic in a Phase 1 trial targeting HER2-positive advanced solid tumors, maintaining its timeline to complete dose escalation by year-end 2026.

PT Aneka Tambang Tbk (ANTAM) reported a historic financial year in 2025, with revenue up 22% and net profit more than doubling to Rp7.92 trillion, driven by strong domestic demand and operational efficiency. The company also navigates evolving Indonesian mining regulations and ongoing legal challenges as it invests in downstream nickel projects.

Acrux Limited has secured a $0.55 million advance on its FY26 R&D Tax Incentive, providing crucial funding to accelerate development of its Hormone Replacement Therapy following FDA regulatory confirmation.

Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals is seeking a re-examination of the European Medicines Agency’s refusal to approve trofinetide for Rett syndrome, aiming to overturn the setback and bring the treatment to European patients.

NeuroScientific Biopharmaceuticals reported a $1.7 million loss for the half-year ending December 2025, driven by ongoing R&D investments. The company progressed clinical treatments for Crohn’s disease and glaucoma, alongside key leadership appointments and strategic partnerships.